Deep Track Capital ENTA Position
Active4-Fund ConvergenceDeep Track Capital initiated a new position in Enanta Pharmaceuticals Inc. (ENTA) in Q4 2025, holding $30.9M worth of shares across 1,956,867 shares.
ENTA is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for zelicapavir in 259 days (Dec 31, 2026), making the timing of Deep Track's position particularly relevant.
About Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Full company profile →Short Interest
8.9%
11.2 days to cover
Frequently Asked Questions
Does Deep Track Capital own ENTA?
Yes. As of Q4 2025, Deep Track Capital holds 1,956,867 shares of Enanta Pharmaceuticals Inc. (ENTA) valued at $30.9M. This data comes from their SEC 13F filing.
How many hedge funds own ENTA?
4 specialist biotech hedge funds currently hold ENTA, including Commodore Capital, RA Capital Management, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy ENTA?
Deep Track Capital's position in ENTA was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's ENTA position increasing or decreasing?
Deep Track Capital initiated a new position in ENTA in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ENTACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →